Jeffrey Jones
About Jeffrey Jones
Jeffrey Jones is the Vice President of Global Drug Development for Lymphoma/Myeloid at Bristol Myers Squibb, with a background in medicine and business.
Company
Jeffrey Jones is currently employed at Bristol Myers Squibb, a prominent pharmaceutical company. As Vice President of Global Drug Development for Lymphoma/Myeloid, he is responsible for overseeing the company's strategic initiatives and development projects in these areas. His work chiefly focuses on the Summit, New Jersey office. Bristol Myers Squibb is known for its commitment to innovation and excellence in the field of oncology.
Title
Jeffrey Jones holds the position of Vice President Global Drug Development, Lymphoma/Myeloid at Bristol Myers Squibb. In this role, he plays a crucial part in guiding the research and development efforts for treatments specific to lymphoma and myeloid diseases. His responsibilities include strategic planning, overseeing clinical trials, and working closely with research teams to ensure successful development of new therapies.
Previous Roles
Before his current role at Bristol Myers Squibb, Jeffrey Jones served as Executive Medical Director at Celgene from 2017 to 2020. At Celgene, he was involved in similar strategic and developmental responsibilities in cancer therapeutics. Prior to that, he was an Associate Professor of Medicine at The Ohio State University from 2006 to 2017, where he had an 11-year tenure contributing to academic and clinical advancements. He has also worked as a Clinical Fellow at MD Anderson Cancer Center and as a Resident Physician at McGill University Health Centre.
Education and Expertise
Jeffrey Jones has an extensive educational background. He earned his M.D. from the University of Michigan Medical School, followed by a Master of Public Health (MPH) focusing on Disease Control from The University of Texas Health Science Center. He also holds a Master of Business Administration (MBA) from The Ohio State University Fisher College of Business. Additionally, he has dual Bachelor's degrees in Economics and English Language and Literature from the University of Maryland College Park.
Professional Contributions
Jeffrey Jones currently serves as the Clinical Co-Chair for the Lymphoma Disease Strategy Team at Bristol Myers Squibb. Since May 2020, he has been instrumental in leading the development of Reblozyl, a therapeutic drug. His professional contributions largely focus on global drug development in the oncology space, specifically for lymphoma and myeloid diseases. His role involves strategic leadership and collaboration with multiple stakeholders within the pharmaceutical industry.